TX-FLUENCE
2.2.2023 14:31:43 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005215/en/
Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire)
Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them.
Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received a medical cannabis license from the Portuguese government. The company is focused on delivering premium quality medicinal cannabis products that adhere to the Good Agricultural and Collection Practice (GACP) and Good Distribution Practices (GDP) wholesale standards, along with all relevant Portuguese regulations.
As a fully indoor facility dedicated to research and development, Key Leaves depends on sole-source lighting for its success—completing more than 20 full cultivation cycles using Fluence LED technology. Fluence’s LEDs have helped Key Leaves optimize production and cultivation light cycles, increase plant yield, uniformity and decrease energy consumption.
“To achieve our business objectives using the most effective and efficient production processes possible, we’ve invested in the world-class technologies and partnerships available,” said Alessandro Radici, CEO at Key Leaves. “Fluence’s market-leading LED technology and the on-call support of its research and horticulture teams allow us to cultivate with maximum efficacy, deliver a highly standardized product and guarantee constant supply for our clients.”
Fluence provides LED lighting solutions to 10 other licensed Portuguese medical cannabis producers—including Bathera, Curaleaf International and Clever Leaves, and pre-licensed AceCann—as well as several additional companies that are currently seeking licensing. Bathera, a German company, recently began producing its own medical cannabis and decided to construct its indoor cultivation and manufacturing facility near Lisbon. The site, currently in progress, houses 6,000 square meters of rooms dedicated to cultivation and 3,000 square meters of space for supporting areas, such as a GMP zone, six drying rooms and space for hand trimming and manual packaging.
“Because of the great Portuguese weather, outdoor cultivation is, of course, possible. We performed rigorous research and analysis with every construction decision and, after looking at the various options, we decided that cultivating indoors is the only way to ensure stable, high-quality products,” said Boris Agababov, founder and CEO of Bathera.
Curaleaf International focuses on advancing the therapeutic value of cannabis used for medicinal purposes to develop products that meet the needs of patients across Europe. The company’s commitment to accessibility, research and data-led product excellence brought it to Fluence when a lighting partner was needed for its Portuguese operations.
“Fluence’s goal is to help our customers grow smarter and build efficient economies of scale,” said Jörg Meyer-Brenken, lead account manager of cannabis in EMEA at Fluence. “We are led by science, and the collaborative approach we take to provide our partners with tailored lighting solutions, knowledge and experience has proven irreplaceable, especially for those in emerging medicinal cannabis markets.”
Portuguese native André Lagareiro, Fluence’s dedicated account manager for Portugal, works closely with Fluence’s Portuguese customers to help them identify the right lighting solutions to optimize plant growth and facility operations.
“Helping companies to innovate and advance medical cannabis operations within Portugal’s legislative environment requires a deep understanding of both cannabis cultivation and European regulatory standards,” said Lagareiro. “The unmatched top-of-the-line product, market expertise and quality of service provided by Fluence’s in-house research and development team is the deciding factor for the many Portuguese cannabis companies that have chosen Fluence as their lighting technology partner.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About AceCann
AceCann is a Portuguese medical cannabis company that has a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon. AceCann is focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities and operating on a flexible structure capable of making fast decisions to scale according to market demands and needs.
About Key Leaves
Key Leaves is a Portuguese-founded company established in 2015 and licensed by Infarmed for the cultivation, import and export of cannabis products. With a multicultural and diversified international team, Key Leaves is proud to be working with some of the most renowned professionals and experts in the medicinal cannabis field.
About Bathera
Bathera is a vertically integrated medical cannabis company with operations in Germany and Portugal. In addition to its state of the art indoor medical cannabis growing facility in Portugal, Bathera, operates two independent wholesalers and importers for medical cannabis in Germany.
About Curaleaf
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021. For more information about Curaleaf International, please visit www.curaleafinternational.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 09:00:00 CEST | Press release
As consumers integrate AI into their everyday web usage, Splio is strengthening its presence in Barcelona to help companies across the region make CRM a central lever in the age of agentic commerce Splio is strengthening its presence in Barcelona, which is set to play the role of a second headquarters, to drive its development across Southern Europe.Splio is reinforcing governance, teams and resources deployed in the region.With its AI-first CRM, Splio aims to help companies from retail to travel strengthen the business contribution of CRM. A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time,
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 08:33:00 CEST | Press release
Longstanding client transitions to the next-generation RRH solution, delivered on Regnology’s Rcloud architecture Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation so
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 08:00:00 CEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 07:00:00 CEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer19.5.2026 07:00:00 CEST | Press release
Experienced biotech finance leader with over 30 years’ experience in capital markets and strategyProven track record in fundraising, M&A and company transformationCompany is currently running two pivotal Phase 3 studies with nizubaglustat in GM1/ GM2 gangliosidoses and Niemann-Pick type C disease Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom